EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms

Christoph J Auernhammer iD, Katharina Wang iD, Umberto Maccio, Thomas Knösel, Maximilian P Hungbauer, Katharina Schilbach iD, Julian Maurer, Lea Peischer, Astrid Reul, Elena Kuzmenko, Edlira Luca, Julia Hamati und 10 weitere

The Journal of Clinical Endocrinology & Metabolism · 2026

DOI: 10.1210/clinem/dgaf705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2026. Verfasst von Christoph J Auernhammer und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Neuroendocrine Tumors, Intestinal Neoplasms, Precision Medicine. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: German Research Foundation, Deutsche Forschungsgemeinschaft, CRC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Precision medicine has transformed many areas in oncology. However, it remains largely unexplored in metastatic gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs), where there is a need for further innovative therapies.

Objective

To evaluate individual tumor responses to different agents, we have established a standardized personalized drug screening and risk assessment platform using patient-derived GEP-NEN primary cultures (n = 23, 16/23 from metastatic tumors, n = 12 small intestinal neuroendocrine tumors [siNETs], n = 10 pancreatic NETs [pNETs], n = 1 neuroendocrine carcinoma [NEC]).

Methods

We assessed GEP-NEN primary culture cell viability, performed signaling pathway analysis by automated Western blotting and immunohistochemically evaluated tumor composition.

Results

Systematic drug testing of 27 agents including signaling inhibitors (i) (mechanistic target of rapamycin inhibitor [mTORi] everolimus, tyrosine kinase inhibitors cabozantinib/sunitinib, AKTi capivasertib, PI3Ki alpelisib, CDK4/6i ribociclib), DNA damage response inhibitors (PARPi niraparib, WEE1i adavosertib, ATRi berzosertib), chemotherapeutics (temozolomide, 5-fluorouracil, lurbinectedin), drug repurposed agents (zoledronic acid), and a personalized risk assessment (glucagon-like peptide [GLP]-2 analogue teduglutide, GLP-1 analogue semaglutide, sex hormones) was performed. We demonstrated statistically significant group effects and individualized responsiveness/resistance data. We identified differences in drug response between pNETs/siNETs and between GEP-NETs/GEP-NEC, respectively.

Conclusion

We provide novel data on the efficacy of putative and established therapies in patient-derived GEP-NEN primary cultures. Our standardized platform for personalized drug screening and risk assessment in GEP-NEN primary cultures enables prediction of individual tumor treatment response in this orphan disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsNeuroendocrine TumorsIntestinal NeoplasmsPrecision MedicineAntineoplastic AgentsStomach NeoplasmsHumansRisk AssessmentFemaleMaleAgedDrug Screening Assays, AntitumorMiddle AgedTumor Cells, Cultured

Stichwörter der Autor:innen

neuroendocrine tumorpersonalized drug testingprecision medicineprimary cultures

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Department of Medicine IV, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Interdisciplinary Center of Neuroendocrine Tumors of the GastroEnteroPancreatic System (GEPNET-KUM, ENETS Centre of Excellence), LMU University Hospital, 81377 Munich, Germany.
  • Department of Pathology and Molecular Pathology, University Hospital Zurich, Zurich CH-8091, Switzerland.
  • Institute of Pathology, Faculty of Medicine, LMU Munich, 80337 Munich, Germany.
  • Department of General, Visceral and Transplantation Surgery, LMU University Hospital, 81377 Munich, Germany.
  • Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich, Zurich CH-8091, Switzerland.

ORCID-Profile: Christoph J Auernhammer, Katharina Wang, Katharina Schilbach, Ralph Fritsch, Felix Beuschlein, Martin Reincke, Constanze Hantel, Kathrin Zitzmann, Svenja Nölting

Förderung

  • German Research Foundation
  • Deutsche Forschungsgemeinschaft
  • CRC
  • Wilhelm Sander-Stiftung

Zitieren

APA

Auernhammer, C. J., Wang, K., Maccio, U., Knösel, T., Hungbauer, M. P., Schilbach, K., Maurer, J., Peischer, L., Reul, A., Kuzmenko, E., Luca, E., Hamati, J., Vetter, D., Oberholzer, J., Fritsch, R., Pacak, K., Grossman, A. B., Beuschlein, F., Reincke, M., …, & Nölting, S. (2026). Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf705

Vancouver

Auernhammer CJ, Wang K, Maccio U, Knösel T, Hungbauer MP, Schilbach K, et al. Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms. The Journal of Clinical Endocrinology & Metabolism. 2026. doi:10.1210/clinem/dgaf705

BibTeX
@article{Auernhammer2026,
  author = {Auernhammer, Christoph J and Wang, Katharina and Maccio, Umberto and Knösel, Thomas and Hungbauer, Maximilian P and Schilbach, Katharina and Maurer, Julian and Peischer, Lea and Reul, Astrid and Kuzmenko, Elena and Luca, Edlira and Hamati, Julia and Vetter, Diana and Oberholzer, Jose and Fritsch, Ralph and Pacak, Karel and Grossman, Ashley B and Beuschlein, Felix and Reincke, Martin and Hantel, Constanze and Zitzmann, Kathrin and Nölting, Svenja},
  title = {Personalized Drug Screening and Risk Assessment in Patient-Derived Gastroenteropancreatic Neuroendocrine Neoplasms},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  doi = {10.1210/clinem/dgaf705}
}
Kostenlos starten →